Zevra Therapeutics
ZVRA | NASDAQ
$9.25
+$0.17 (+1.87%)
At close: Nov 16, 2026, 4:00 PM ET
$9.25
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Zevra Therapeutics Company Profile
Company profile explainedCompany Profile
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
Key Executives
| Name | Position |
|---|---|
| Neil F. McFarlane | President, Chief Executive Officer & Director |
| Alison Peters | Chief People Officer |
| Justin A. Renz | Chief Financial Officer & Treasurer |
| Rahsaan W. Thompson | Chief Legal Officer, Secretary & Compliance Officer |
| Adrian Quartel FFPM | Consultant |
| Christopher Lauderback | Senior Vice President of Manufacturing |
| Gerald J. Orehostky | Senior Vice President of Regulatory Affairs & Quality |
| Joshua Schafer | Chief Commercial Officer |
| Nichol L. Ochsner | Vice President of Investor Relations & Corporate Communications |
| Tanya Hayden | Senior Vice President & Chief of Staff |
| Timothy J. Sangiovanni | Senior VP of Finance & Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 13, 2026 | 4 | Filing |
| Aug 17, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | 4 | Filing |
| Aug 06, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Jul 31, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jun 23, 2026 | 4 | Filing |
| Jun 18, 2026 | 4 | Filing |
Zevra Therapeutics
| Country | United States |
| IPO Date | Apr 16, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 61 |
| CEO | Neil F. McFarlane |
Contact Details
101 Federal Street Boston,
Massachusetts 02110 United States
Stock Details
| Ticker Symbol | ZVRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001434647 |
| CUSIP Number | 488445206 |
| ISIN Number | US4884452065 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove ZVRA